🇺🇸 FDA
Patent

US 12042529

Optimization of enzyme replacement therapy for treatment of homocystinuria

granted A61KA61K38/51A61K47/60

Quick answer

US patent 12042529 (Optimization of enzyme replacement therapy for treatment of homocystinuria) held by The Regents of the University of Colorado, a Body Corporate expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/51, A61K47/60